Market Context — Why This Technology, Why Now

The global healthcare landscape is rapidly shifting towards proactive wellness and personalized medicine, driven by increasing consumer demand for preventative solutions and performance optimization. Regulatory bodies are also encouraging innovation in functional ingredients and therapeutic agents that address chronic metabolic conditions. This technology aligns perfectly with these trends, offering a scientifically validated pathway to develop products that not only treat but also prevent disease, catering to a market eager for effective, long-term health management tools.

Key Competitive Advantages
01

Achieves High Efficacy via Novel Mechanism of Action: Specifically binds to PPARδ via guanidine or biguanidine derivatives, activating metabolism through a distinct pathway from existing drugs, potentially offering high efficacy with reduced side effects.

02

Offers Multifaceted Contribution to Exercise Tolerance and Metabolic Improvement: Improves not only physical performance but also fundamentally enhances systemic energy metabolism, applicable to a wide range of health issues including lifestyle disease prevention/treatment and obesity management.

03

Ensures Strong IP for Market Dominance: Secures a robust patent, validated through rigorous examination against multiple prior art documents, ensuring exclusive market deployment until 2043.

Market Opportunity
Pharmaceuticals (Metabolic Disease Therapeutics)
$40B globally (AI est.)
The increasing prevalence of metabolic diseases like diabetes, obesity, and dyslipidemia drives demand for novel therapeutic agents with new mechanisms of action.
Large pharmaceutical companies Biotech firms specializing in metabolic disorders Contract research organizations (CROs) for drug development
Functional Foods & Supplements
$20B globally (AI est.)
Growing health consciousness fuels the expansion of functional foods and supplements aimed at exercise support and metabolic improvement, offering a differentiated product development opportunity for this technology.
Global nutraceutical companies Sports nutrition brands Health and wellness product manufacturers
Preventive Healthcare & Wellbeing Solutions
$6.5B globally (AI est.)
The accelerating societal shift towards disease prevention and health maintenance creates opportunities for new services and products that leverage this technology to support individual health promotion.
Digital health platform providers Corporate wellness program developers Personalized medicine companies
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a novel PPARδ activator based on guanidine or biguanidine derivatives, specifically covering their unique binding mechanism to PPARδ. The robust claims, validated through rigorous examination against prior art, suggest a strong and difficult-to-invalidate intellectual property.

Competitive White Space

This patent focuses on specific guanidine and biguanidine derivatives as PPARδ activators. White space exists in developing alternative chemical scaffolds for PPARδ activation, exploring synergistic combination therapies, or innovating novel drug delivery systems for these compounds.

Economic Impact
~$2M/year estimated healthcare cost reduction (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

This technology could contribute to reducing healthcare costs related to lifestyle diseases by improving metabolism and exercise tolerance. Assuming annual lifestyle disease-related healthcare costs of ~$40B (AI est.) in Japan, a 0.005% improvement could yield an estimated ~$2M/year (AI est.) in healthcare cost savings. This is a conservative estimate, not including the economic value of improved quality of life from enhanced exercise capacity.

Speed to Market
3× faster than in-house development
This patent covers the foundational research phase, including the identification of novel PPARδ agonists, detailed analysis of their mechanism of action, and preliminary indications of improved exercise tolerance. Licensees can significantly reduce the initial R&D period for compound design, synthesis, and activity evaluation, accelerating commercialization by potentially ~3.5 years by starting from non-clinical and clinical development phases.
Competitive Positioning

X: Metabolic Improvement Specificity
Y: Contribution to Exercise Function Enhancement

Business Models & Applications
💊 Novel Pharmaceutical Development & Sales
Development and commercialization of groundbreaking therapeutic drugs targeting metabolic diseases such as obesity, diabetes, and NASH (Non-alcoholic steatohepatitis), based on this technology.
🏋️ Functional Food & Supplement Business
Development, manufacturing, and sales of functional foods and health supplements aimed at improving exercise performance, accelerating fatigue recovery, and reducing body fat.
🧬 Personalized Medicine Solutions
Application in diagnostic drug development using PPARδ activity as a biomarker, or in personalized exercise and nutrition programs based on genetic information, with associated service provision.
Adjacent Application Opportunities
🏋️ スポーツ・健康
Performance Enhancement Supplements for Elite Athletes
Focusing on improved exercise tolerance, this technology could be developed into supplements that boost endurance and recovery. Products could help elite athletes maximize their potential and achieve higher performance levels.
🏥 医療機器・診断
Personalized Nutrition & Exercise Guidance Programs
Combine this PPARδ activator with biomarkers to predict responsiveness, creating digital health programs that offer personalized nutrition and exercise prescriptions. This could support more effective individual health management.
🍎 食品加工・開発
Functional Foods for Metabolic Health
Leveraging the metabolic improvement effects, this technology could be developed into functional foods or beverages targeting general consumers. Positioning as a scientifically-backed product could enhance market trust and competitiveness.
Integration Roadmap — Estimated 49-Month Deployment
Phase 1: Technology Evaluation & Initial Design
Duration: 4 months
Detailed evaluation of this technology and verification of its compatibility with the licensee's existing R&D resources. Formulation of product concepts and initial compound design.
Phase 2: Non-Clinical Trials & Prototype Development
Duration: 15 months
Synthesis of optimized compounds and execution of non-clinical trials (pharmacology, safety, etc.). For functional foods or supplements, prototype development and efficacy verification.
Phase 3: Clinical Development & Commercialization Strategy
Duration: 30 months
Initiation of clinical trials for pharmaceuticals. For functional foods, regulatory compliance and establishment of mass production systems. Development of marketing and sales strategies for market launch.
Technical Feasibility
This technology provides clear compound design guidelines by disclosing the detailed mechanism of how guanidine or biguanidine derivatives hydrogen-bond with specific amino acid residues within the PPARδ ligand-binding pocket. This allows licensees to leverage existing drug discovery platforms and compound library for efficient screening and structural optimization. Technical feasibility is high, as it can be seamlessly integrated into existing R&D structures while minimizing new capital investment.
Success Scenario
By adopting this technology, licensees could develop innovative products addressing broad needs in lifestyle disease prevention/treatment and exercise function improvement. This could establish market leadership ahead of competitors and potentially increase annual revenues by several percentage points, leveraging the long exclusivity period until 2043. It is also estimated to enhance corporate value and contribute to extending healthy life expectancy.
Patent Record
APPLICATION NO.
特願2023-149458
REGISTRATION NO.
7630854
FILING DATE
2023/09/14
GRANT DATE
2025/02/07
EXPIRATION DATE
2043/09/14
PATENT HOLDER
国立研究開発法人科学技術振興機構
Examination History
2023年09月14日
手続補正書（自発・内容）
2023年09月14日
出願審査請求書
2024年09月10日
拒絶理由通知書
2024年11月07日
手続補正書（自発・内容）
2024年11月07日
意見書
2025年01月07日
特許査定